Patient need for novel therapies in ROS1 fusion-positive non-small cell lung cancer

ROS1+ NSCLC patients have benefited from existing therapies like crizotinib. However, there are unmet needs for novel therapies to address drug resistance, brain metastasis, neurologic and cognitive side effects, and short duration of response. Several investigational new therapies may provide solutions.

Join our webinar to learn about:
  • The current treatment landscape for patients with ROS1+ NSCLC
  • Differences between the different ROS1 inhibitors either already approved or in development
  • How to improve outcomes for all ROS1+ cancers

A live Q&A session will follow the discussion.

watch now
Watch the webinar on demand
David Ross Camidge

David Ross Camidge

Director of Thoracic Oncology, Joyce Zeff Chair in Lung Cancer Research, University of Colorado Cancer Center

Dr. Camidge, M.D., Ph.D., is the Director of Thoracic Oncology at the University of Colorado. His focus is in Thoracic Malignancies and Developmental Therapeutics (Phase I studies). In 2012, he was announced as the recipient of the 5th Bonnie J. Addario Lectureship as a ‘Luminary in the quest to eradicate lung cancer.’ In 2013, he became the first physician to receive the Hank Baskett Sr. Spirit Award, for which he was credited as being ‘one of the leading minds in lung cancer today.’ In 2015, he became the inaugural holder of the Joyce Zeff Chair in Lung Cancer Research at the University of Colorado Cancer Center and in 2016, the Lung Cancer Foundation presented him with the Breath Away From The Cure Award describing him as ‘Simply one of the best in treating lung cancer today.’

Dr. Camidge is also the National Medical Director of the Academic Thoracic Oncology Medical Investigators Consortium (ATOMIC) and a member of the National Comprehensive Cancer Network Lung Cancer Committee.

In addition to training Fellows through the CU ACGME Medical Oncology Fellowship, Dr Camidge is also the Director of the CU Senior Thoracic Oncology Clinical and Translational Research Fellowship - a unique ‘finishing school’ in advanced cancer clinical research for US and International Graduates who have already completed their basic Medical Oncology training. Through these two programs, Dr Camidge has mentored a consistent series of outstanding early career medical oncologists. In 2014, he was nationally recognized by The Quality of Life Center at Claremont University in California as an ‘Exemplary mentor in the positive development of junior colleagues in the profession.'

Misako Nagasaka

Misako Nagasaka

Thoracic Oncologist, Associate Professor, University of California Irvine

Dr. Nagasaka, M.D., Ph.D., is a board-certified thoracic oncologist at the University of California - Irvine who specializes in the diagnosis and treatment of lung and thyroid cancer. Her clinical interests also include early-phase clinical trials, medical ethics and survivorship care for patients. She received her medical degree as well as a Ph.D. from St. Marianna University School of Medicine in Kawasaki, Japan. She completed a residency in internal medicine at Mount Sinai Beth Israel Hospital in New York City, followed by a fellowship in hematology and oncology at Wayne State University School of Medicine's Karmanos Cancer Institute.

Janet Freeman-Daily

Janet Freeman-Daily

Cancer Research Advocate, Co-Founder & President, The ROS1ders

Janet is a cancer patient research advocate and activist who translates the experience and science of cancer for others. She was diagnosed with advanced lung cancer in 2011 and metastatic ROS1+ lung cancer in 2012. She collaborates, writes, and speaks with cancer organizations both internationally and within the USA, and blogs at Gray Connections. Janet previously worked as an aerospace systems engineer.